A detailed history of Voya Investment Management LLC transactions in Alector, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 27,833 shares of ALEC stock, worth $126,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,833
Previous 22,247 25.11%
Holding current value
$126,640
Previous $133,000 5.26%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$4.19 - $6.23 $23,405 - $34,800
5,586 Added 25.11%
27,833 $126,000
Q1 2024

May 15, 2024

SELL
$5.69 - $8.08 $21,047 - $29,887
-3,699 Reduced 14.26%
22,247 $133,000
Q3 2023

Nov 14, 2023

BUY
$5.2 - $8.77 $3,317 - $5,595
638 Added 2.52%
25,946 $168,000
Q2 2023

Aug 14, 2023

BUY
$5.86 - $7.93 $5,104 - $6,907
871 Added 3.56%
25,308 $152,000
Q3 2022

Nov 14, 2022

BUY
$8.19 - $13.2 $12,866 - $20,737
1,571 Added 6.87%
24,437 $231,000
Q4 2021

Feb 14, 2022

BUY
$19.35 - $25.54 $1,509 - $1,992
78 Added 0.34%
22,866 $472,000
Q2 2021

Aug 16, 2021

BUY
$15.5 - $22.48 $35,030 - $50,804
2,260 Added 11.01%
22,788 $475,000
Q1 2021

May 17, 2021

BUY
$14.84 - $22.23 $7,894 - $11,826
532 Added 2.66%
20,528 $413,000
Q4 2020

Feb 16, 2021

BUY
$9.4 - $16.7 $37,665 - $66,916
4,007 Added 25.06%
19,996 $303,000
Q2 2020

Aug 14, 2020

SELL
$21.87 - $33.11 $25,194 - $38,142
-1,152 Reduced 6.72%
15,989 $391,000
Q1 2020

May 15, 2020

BUY
$16.25 - $35.28 $40,803 - $88,588
2,511 Added 17.16%
17,141 $414,000
Q4 2019

Feb 14, 2020

BUY
$14.17 - $20.3 $45,046 - $64,533
3,179 Added 27.76%
14,630 $252,000
Q3 2019

Nov 14, 2019

BUY
$14.42 - $22.2 $165,123 - $254,212
11,451 New
11,451 $165,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $376M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.